$3M Gene Therapy—With a Catch - Report - MDSpire

$3M Gene Therapy—With a Catch

Medicaid is testing a pay-for-performance deal that makes drugmakers refund millions if new sickle cell gene therapies fail.

  • By

  • Phil Galewitz

  • January 21, 2026

  • 8 min

Share

Clinical Report: $3M Gene Therapy—With a Catch

Overview

Expand on the payment model's structure and its potential effects on patient care.

Background

Sickle cell disease is a genetic condition affecting approximately 100,000 Americans, predominantly impacting the Black community and significantly shortening lifespans. The introduction of gene therapies offers a potential cure, but the high costs associated with these treatments pose challenges for Medicaid, which covers nearly half of the affected population. Understanding the implications of these therapies and their payment models is crucial for healthcare providers and policymakers.

Data Highlights

No numerical data available.

Key Findings

  • Serenity Cole, an 18-year-old with sickle cell disease, underwent a gene therapy treatment that reprograms stem cells to produce healthy red blood cells.
  • The cost of the gene therapies is approximately $2.2 million and $3.1 million, not including hospital stay expenses.
  • The Centers for Medicare & Medicaid Services (CMS) has initiated a payment model where drug manufacturers are held accountable for treatment outcomes.
  • 33 states, Washington D.C., and Puerto Rico have signed onto the new Medicaid initiative for gene therapy payments.
  • Clinical trials for the therapies reported high rates of freedom from severe vaso-occlusive crises (VOCs) for treated patients.
  • Concerns remain regarding the long-term efficacy and financial sustainability of these high-cost therapies.

Clinical Implications

Healthcare providers should be aware of the new gene therapy options for sickle cell disease and the associated costs. The innovative payment model may influence treatment accessibility and should be monitored for its effectiveness in improving patient outcomes.

Conclusion

Highlight the importance of further research on long-term outcomes and financial sustainability.

References

  1. Retinal Physician, March 2023 -- UPFRONT: Gene Therapy's Price Tag
  2. Retinal Physician, October 2015 -- What’s New in Gene Therapy for Ophthalmology?
  3. Ophthalmology Management, July 2024 -- Gene Therapy for Retinal Disease Recommendations
  4. CASGEVY | FDA -- FDA Approval Information
  5. Retinal Physician — The Eye as a Biofactory
  6. CASGEVY | FDA
  7. The new england
  8. Gene therapy for sickle cell disease: Practice recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy - PMC

Original Source(s)

$3M Gene Therapy—With a Catch

  • by Phil Galewitz

  • January 21, 2026

Related Content

IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.

Using GPT-4 to annotate the severity of all phenotypic abnormalities within the human phenotype ontology

Mutational Signatures May Define Oral Cancers

Researchers identified endogenous mutational and immune-response patterns in oral cancers arising without exposure to tobacco, alcohol, or human papillomavirus infections.